Icahn Finds His Way Back To Pharma

Carl Icahn dropped a note today that he’s now long one of the more interesting large-cap big pharma stocks. Per Icahn, he recently acquired a large position in Allergan and is “very supportive of CEO Brent Saunders. We were instrumental in bringing Brent on board as the new CEO of Forest Labs a few years ago and worked cooperatively and constructively with him to help increase value for all Forest shareholders. Less than a year later Forest was acquired by Actavis (which subsequently merged with Allergan) resulting in massive gains for Forest shareholders. While we at that time disposed of our position in Forest, we still have always maintained great respect for Brent. We have every confidence in Brent’s ability to enhance value for all Allergan shareholders.” Allergan might be worth a deeper dive. The company took a hit after the government blocked its merger with Pfizer. We’ve rolled out the billing feature for our premium product. You can now choose how to be invoiced, as well as how and when you want to pay. Check it out here. Now, Allergan is the maker of Botox and Juvederm. By all accounts, Icahn hasn’t shown up to push for change here or another mega-merger. This will be somewhat of a passive stake for him. He’s looking to capitalize on the selloff and ride the Brent Saunders wave. Shares are down nearly 30% from their 52-week high and off 23% this year. Don’t forget: We’ve rolled out the billing feature for our premium product. You can now choose how to be invoiced, as well as how and when you want to pay. Check it out here.

Activist Stocks · 20 East Third Street · Charlotte, NC 28202 · USA